Search
Returning search results with filters:
Remove filter for
Type: Health professional risk communication
Clear all
Search filters
Type
Audience
Category
Issue
Last updated
Displaying 1 - 15 of 120 items.
Important Safety and Efficacy Information on ALBRIOZA (sodium phenylbutyrate and ursodoxicoltaurine) – Market Withdrawal and Continued Restricted Access
AlertHealth professional risk communication | 2024-06-07
Importation of USA-authorized Carbamazepine Extended-Release Tablets, USP 200 mg and 400 mg due to the current shortage of Canadian-authorized carbamazepine
AlertHealth professional risk communication | 2024-06-05
Importation of Italian-authorized Cisatracurio Hikma 2 mg/mL Ampoules due to the Current Shortage of Canadian-authorized Cisatracurium Omega
AlertHealth professional risk communication | 2024-04-24
Ezetrol (ezetimibe) and the Risks of Drug-Induced Liver Injury and Severe Cutaneous Adverse Reactions
AlertHealth professional risk communication | 2024-03-27
Paclitaxel-Coated Balloons (PCB) and Paclitaxel-Eluting Stents (PES) for the Treatment of Peripheral Arterial Disease (PAD) and the Potential Risk of Long-Term All-Cause Mortality
AlertHealth professional risk communication | 2024-02-20
Importation of UK-Authorized Potassium Chloride 15% w/v Concentrate for Solution for Infusion due to shortage of Canadian-authorized Potassium Chloride for Injection Concentrate
AlertHealth professional risk communication | 2023-10-24
Baxter Intravenous Solution Bags – Potential Leak During Spiking of Administration Port
AlertHealth professional risk communication | 2023-10-06
IDHIFA (enasidenib mesylate) – Market Withdrawal and Continued Access
AlertHealth professional risk communication | 2023-06-08
ISTODAX (romidepsin) – Restricted Access Program
AlertHealth professional risk communication | 2023-03-20
ZEJULA (niraparib) - Update on the Maintenance Treatment in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in the Second or Later Line Setting
AlertHealth professional risk communication | 2023-02-16
RUZURGI (amifampridine) - Authorization Status
AlertHealth professional risk communication | 2023-01-20
EVUSHELD (tixagevimab and cilgavimab for injection) - Risk of Prophylaxis or Treatment Failure due to Antiviral Resistance to specific SARS-CoV-2 Subvariants
AlertHealth professional risk communication | 2023-01-17
COMIRNATY Original & Omicron BA.4/BA.5 Bivalent Vaccine with English-only Vial and Carton Labels: New Formulation for Use in Children 5 to Less Than 12 Years of Age
AlertHealth professional risk communication | 2022-12-09
OCALIVA (obeticholic acid) – New Contraindication for the Treatment of Primary Biliary Cholangitis (PBC)
AlertHealth professional risk communication | 2022-12-05
SPIKEVAX Bivalent (Original / Omicron BA.4/5) (elasomeran/davesomeran) COVID-19 Vaccine with English-only Vial and Carton Labels
AlertHealth professional risk communication | 2022-11-18